Vincenzo Lagani1, Franco Chiarugi2, Shona Thomson3, Jo Fursse4, Edin Lakasing4, Russell W Jones4, Ioannis Tsamardinos5. 1. Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklion, Greece. Electronic address: vlagani@ics.forth.gr. 2. Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklion, Greece. 3. Herts Valley Clinical Commission Group, Hertfordshire, United Kingdom. 4. Chorleywood Health Center, Chorleywood, United Kingdom. 5. Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklion, Greece; Computer Science Department, University of Crete, Heraklion, Greece.
Abstract
AIM: To derive and validate a set of computational models able to assess the risk of developing complications and experiencing adverse events for patients with diabetes. The models are developed on data from the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) studies, and are validated on an external, retrospectively collected cohort. METHODS: We selected fifty-one clinical parameters measured at baseline during the DCCT as potential risk factors for the following adverse outcomes: Cardiovascular Diseases (CVD), Hypoglycemia, Ketoacidosis, Microalbuminuria, Proteinuria, Neuropathy and Retinopathy. For each outcome we applied a data-mining analysis protocol in order to identify the best-performing signature, i.e., the smallest set of clinical parameters that, considered jointly, are maximally predictive for the selected outcome. The predictive models built on the selected signatures underwent both an interval validation on the DCCT/EDIC data and an external validation on a retrospective cohort of 393 diabetes patients (49 Type I and 344 Type II) from the Chorleywood Medical Center, UK. RESULTS: The selected predictive signatures contain five to fifteen risk factors, depending on the specific outcome. Internal validation performances, as measured by the Concordance Index (CI), range from 0.62 to 0.83, indicating good predictive power. The models achieved comparable performances for the Type I and, quite surprisingly, Type II external cohort. CONCLUSIONS: Data-mining analyses of the DCCT/EDIC data allow the identification of accurate predictive models for diabetes-related complications. We also present initial evidences that these models can be applied on a more recent, European population.
AIM: To derive and validate a set of computational models able to assess the risk of developing complications and experiencing adverse events for patients with diabetes. The models are developed on data from the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) studies, and are validated on an external, retrospectively collected cohort. METHODS: We selected fifty-one clinical parameters measured at baseline during the DCCT as potential risk factors for the following adverse outcomes: Cardiovascular Diseases (CVD), Hypoglycemia, Ketoacidosis, Microalbuminuria, Proteinuria, Neuropathy and Retinopathy. For each outcome we applied a data-mining analysis protocol in order to identify the best-performing signature, i.e., the smallest set of clinical parameters that, considered jointly, are maximally predictive for the selected outcome. The predictive models built on the selected signatures underwent both an interval validation on the DCCT/EDIC data and an external validation on a retrospective cohort of 393 diabetespatients (49 Type I and 344 Type II) from the Chorleywood Medical Center, UK. RESULTS: The selected predictive signatures contain five to fifteen risk factors, depending on the specific outcome. Internal validation performances, as measured by the Concordance Index (CI), range from 0.62 to 0.83, indicating good predictive power. The models achieved comparable performances for the Type I and, quite surprisingly, Type II external cohort. CONCLUSIONS: Data-mining analyses of the DCCT/EDIC data allow the identification of accurate predictive models for diabetes-related complications. We also present initial evidences that these models can be applied on a more recent, European population.
Authors: Sisi Ma; Pamela J Schreiner; Elizabeth R Seaquist; Mehmet Ugurbil; Rachel Zmora; Lisa S Chow Journal: J Biomed Inform Date: 2020-01-28 Impact factor: 6.317
Authors: Emily B Schroeder; Stan Xu; Glenn K Goodrich; Gregory A Nichols; Patrick J O'Connor; John F Steiner Journal: J Diabetes Complications Date: 2017-04-11 Impact factor: 2.852
Authors: Dennis H Murphree; Elaheh Arabmakki; Che Ngufor; Curtis B Storlie; Rozalina G McCoy Journal: Comput Biol Med Date: 2018-10-16 Impact factor: 4.589
Authors: An Tran-Duy; Josh Knight; Andrew J Palmer; Dennis Petrie; Tom W C Lung; William H Herman; Björn Eliasson; Ann-Marie Svensson; Philip M Clarke Journal: Diabetes Care Date: 2020-06-12 Impact factor: 19.112